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undetectable by computed tomography (CT) scan. We 
are not given this information in the first study, but 
benign regenerative nodules are typically not visible by 
CT. If a focal lesion is confirmed by CT scan, again the 
question of malignancy should be raised. (d) Most lesions 
in the first study but not the second study enlarged with 
follow-up, which should also suggest HCC. 
So what should we do with the asymptomatic patient 
with known cirrhosis and a focal lesion demonstrated by 
ultrasound? Most are going to have HCC. If the 
a-fetoprotein (AFP) level is high (> 1,000 ng/ml), the 
patient almost certainly has HCC, and histological 
confirmation may not be necessary. A low AFP does not 
rule out malignancy. Although CT scan is not feasible for 
screening programs in the Far East, in the United States 
most ultrasound lesions will be confirmed by CT before 
obtaining the histological study. Ultrasound-guided, 
FNA should then be performed and, if histologically 
benign, repeated with a thin liver-biopsy needle. If the 
diagnosis of HCC is not made, the prudent course is to 
observe the patient. A rising AFP level and/or sono- 
graphic enlargement of the lesion should prompt further 
invasive evaluation by either an ultrasound-guided or 
laparoscopic biopsy procedure. 
Are regenerative nodules premalignant lesions? The 
cirrhotic liver per se is associated with an increased risk 
of HCC, the risk varying with the cause of the liver 
disease. However, regenerative nodule is not synon- 
ymous with focal liver lesion. Every focal mass lesion in 
a cirrhotic liver should simply be considered malignant 
until proven otherwise (e.g., with a follow-up of more 
than 2 yr without observed progression). With careful 
evaluation, most will be shown to be malignant initially. 
The evidence that large regenerative nodules have 
greater malignant potential than the surrounding cir- 
rhotic liver is slim at best. 
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LIVER TRANSPLANTATION RESTORES FEMALE 
REPRODUCTIVE ENDOCRINE FUNCTION 
Cundy TF, O'Grady JG, Williams R. Recovery of 
menstruation and pregnancy after liver transplantation. 
Gut 1990;31:337-338. 
ABSTRACT 
The effect of successful liver transplantation on 
menstrual function was assessed by questionnaire in 44 
women transplanted for various types of end stage liver 
disease, acute liver failure or malignant disease. Sig- 
nificant amenorrhoea ( >one year) was present in 48% 
of women with chronic liver disease before transplan- 
tation, and was reversed within 10 months of surgeryin 
all but one of the pre-menopausal patients who had 
primary amenorrhoea and hypogonadotrophic hypo- 
gonadism. Two patients became pregnant five months 
and 1-5 years after transplantation, but in one instance 
the pregnancy waa umuccessful, possibly as a conse- 
quence of cyclosporin related intrauterine growth 
retardation. 
Scantlebury V, Gordon R, Tzakis A, Koneru B, Bow- 
man J, Mazzaferro V, Stevenson WC, et al. Childbearing 
after liver transplantation. Transplantation 1990;49: 
ABSTRACT 
Seventeen female patients who underwent ortho- 
topic liver transplantation between June 1973 and 
June 1987 became pregnant 5 months to 11 years 
after transplantation. Immunosuppression was main- 
tained with combinations of prednisone, cycloeporine, 
and azathioprine prior to and during pregnancy. 
One patient discontinued immunosuppression after 
knowledge of pregnancy, taking only azathioprine 
sporadically. Mean age at time of delivery was 26 years. 
Twelve patients had no alteration in liver function 
studies; 7 patients demonstrated mild or moderate 
enzyme elevations prior to delivery, with one case of 
rejection confirmed by percutaneous liver biopsy. 
Mdor problems related to pregnancy were hyper- 
tension, anemia, and hyperbilirubinemia. Twenty live 
births occurred (2 patients had 2 separate pregnancies, 
one patient has a set of twins); 13 were by caesarian 
section, 7 by vaginal delivery. Eleven of the 13 cae- 
sarian births were premature by gestational age. All 
vaginal births were term. Toxemia of pregnancy and 
early rupture of membranes were the principal indi- 
cations for caesarean section. 
There were no congenital abnormalities or birth 
defects and all the children are surviving well. Fif- 
teen of 16 children older than one year have normal 
physical and mental development, with one child 
manifesting immature speech development. Four 
children are under one year, all with normal mile- 
stones thus far. Sixteen of the 17 mothers are alive 
from 2-18 years after transplantation; the only death 
was from a lymphoma, almost 4 years after transplan- 
tation and 2% years after delivery. This experience 
suggests that women undergoing liver transplantation 
can safely bear children despite an increased risk of 
premature caesarian births. The effect of chronic 
immunosuppression of female pediatric patients on 
their reproductive potential later in adulthood re- 
mains to be fully evaluated but the results so fa r  are 
favorable. 
COMMENTS 
In the past 20 yr, liver transplantation has emerged as 
the treatment of choice for many symptomatic patients 
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with acute and chronic liver disease. Now that an 80% 
1-yr survival rate is commonplace, and long-term sur- 
vival beyond this is expected in many liver transplant 
recipients, patients and physicians have begun to look 
beyond quantity of life to  quality of life after transplan- 
tation. The endocrine and tissue abnormalities under- 
lying sexual dysfunction in cirrhosis are complex, and 
their potential for reversal with liver transplantation are 
important issues in determining restoration of normal 
sexual and reproductive function. The two articles under 
review provide valuable information for female patients 
who are undergoing liver transplantation evaluation 
when they inquire whether menstruation, conception 
and pregnancy are possible after liver transplantation. 
To date, most work describing changes in the 
hypothalamic-pituitary-gonadal axis in patients with 
chronic liver disease has focused on alcoholic patients. I t  
has been suggested that alcohol rather than the chronic 
liver disease itself may account for many of the changes 
seen in these patients (1). Men with alcoholic liver 
disease exhibit testicular atrophy, impotence and de- 
creased libido. It has been suggested that a change in the 
redox state in the testes or the accumulation of acetal- 
dehyde may interfere with steroidogenesis or have a 
direct toxic effect on the cells (1). Interference with 
normal metabolism of vitamin A (necessary for sper- 
matogenesis) may also play a role (1). Similarly, women 
with alcoholic liver disease exhibit ovulatory failure, 
reduced estradiol and progesterone levels and loss of 
secondary sexual characteristics. The biochemical mech- 
anism may be similar to that seen in alcoholic men (1). 
In addition, alcoholic men and women both show 
evidence of a central hypothalamic-pituitary defect in 
gonadotropin secretion (1). In contrast, men with 
presumed chronic viral liver disease have normal levels 
of testosterone and maintain an appropriate luteinizing- 
hormone (LH) response to the LH releasing factor when 
compared with alcoholic men (2). Studies of women with 
nonalcoholic liver disease have not been conducted to the 
same extent. However, hypothalamic-pituitary-gonadal 
function in women with nonalcoholic forms of cirrhosis 
is frequently abnormal, as shown by the incidence of 
prolonged amenorrhea in female cirrhotic patients 
before liver transplantation as reported by Cundy, 
O’Grady and Williams. 
Few reports discuss the effect of liver transplantation 
on the hypothalamic-pituitary-gonadal function. Re- 
cently, Van Thiel et al. (3) evaluated these issues in 
alcoholic and nonalcoholic men undergoing transplan- 
tation. Compared with nonalcoholic men, alcoholic men 
exhibited decreased plasma levels of testosterone, 
follicle-stimulating hormone (FSH) and LH before 
transplantation. Additionally, they reported a greater 
frequency and severity of impotence. After successful 
liver transplantation, plasma levels of FSH, LH and 
testosterone returned toward normal levels, and these 
hormonal changes were accompanied by a reduction in 
the frequency and severity of impotence in the alcoholic 
men. They suggest that liver transplantation in alco- 
holic cirrhotic men improves the functioning of the 
hypothalamic-pituitary-gonadal axis considerably but 
does not return it to complete normalcy (3). 
Heretofore, data concerning reproductive endocrine 
function in female liver transplant recipients consisted 
of case reports describing pregnancy and parenthood 
after liver transplantation (4). The papers by Cundy, 
O’Grady and Williams and Scantlebury et al. are the first 
collective descriptions of menstrual patterns and preg- 
nancy in women after liver transplantation. Cundy and 
colleagues specifically address the question of recovery 
of menstruation after liver transplantation. Of 34 
patients, 28 resumed menstruation within 10 mo of 
transplantation, and 5 patients appeared to be post- 
menopausal because of age and elevation of FSH and 
LH. Most interesting was the observation that menstru- 
ation returned within 2 mo after transplantation in 41% 
of the patients and by 5 mo in 79% of the patients. This 
suggests the underlying defect is corrected quickly and 
that one needs to counsel patients concerning the need 
for contraception as soon as sexual activity is resumed if 
pregnancy is not desired. 
The outcome of pregnancy when it does occur after 
transplantation seems to be fairly good. Scantlebury 
et al. describe 17 patients who became pregnant after 
liver transplantation and explain several important 
points. First, graft function appeared to be maintained 
throughout pregnancy and delivery. Thirty-five percent 
of pregnant patients had a rise in transaminase levels, 
but only one episode of acute rejection was documented. 
After delivery, 10 of 17 patients had elevated enzymes. 
Four patients were treated empirically for rejection with 
only one of four responding, suggesting that of these 
patients, even in this low incidence, rejection may have 
been overdiagnosed. Because of the confounding inci- 
dence of hypertension and toxemia in this series, it is 
difficult to interpret these moderate biochemical 
changes. First, it is known that up to 60% of patients 
with toxemia of pregnancy may exhibit moderate trans- 
aminase elevations (5). Second, the major maternal 
complications seen were hypertension and anemia. It is 
likely that cyclosporine contributed to the high incidence 
of hypertension and toxemia in these patients. Sixty- 
three percent of the patients had deliveries by Cesarean 
section, a rate much higher than the 24% rate usual in 
the United States (6). Nonetheless, no maternal deaths 
were reported. Third, despite continued immunosup- 
pression in 16 of 17 patients, infants born to these 
mothers generally did well. Overall, only one infant 
required mechanical ventilation. No infections or other 
complications were seen. Although fears exist that 
prednisone or azathioprine may have teratogenic con- 
sequences, the lack of congenital abnormalities observed 
in this series is in accord with observations on the use of 
these agents in pregnant renal transplant recipients or 
patients with inflammatory bowel disease (7); Cyclo- 
sporine crosses the placenta readily (Bourget, et al. 
Transplantation 1990;49:663-664, Correspondence) but 
has not been shown to produce congenital abnormalities. 
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The possibility that it may result in intrauterine growth 
retardation has been suggested (8,9), and that was seen 
in three patients in the Scantlebury et al. series and one 
patient reported by Cundy, O’Grady and Williams. The 
importance of this is unclear, given that intrauterine 
growth retardation can be seen in up to 10% of ostensibly 
normal pregnancies. 
The single case reported in the Scantlebury et al. 
article of a patient who stopped all medication in 
pregnancy is fascinating. Pregnancy is a state of altered 
immunity allowing retention of a foreign tissue mass 
(the fetus). The low incidence of allograft rejection 
reported by Scantlebury et al. and the successful 
withdrawal of immunosuppressive agents, albeit in one 
recipient only, imply that lower doses of immunosup- 
pressive agents may be effective during pregnancy. 
It appears from these articles that (a) menstruation 
returns in concert with restored hepatic function, and 
(b) pregnancy is possible and relatively safe after 
liver transplantation. Indeed, liver transplantation can 
sustain the life of mother and fetus even in the extreme 
circumstances of decompensated liver failure during 
pregnancy (10). All in all, these articles contain reas- 
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URSODEOXYCHOLIC ACID AND TAURINE AS 
THERAPY FOR CHOLESTATIC LIVER DISEASE 
Podda M ,  Ghezzi C, Battezzati PM, Crosignani A, Zuin 
M, Roda A. Effects of ursodeoxycholic acid and taurine 
on serum liver enzymes and bile acids in chronic 
hepatitis. Gastroenterology 1990;98:1044-1050. 
ABSTRACT 
Relatively hydrophobic bile acids have been shown 
to produce some hepatotoxicity, whereas treatment 
with a more hydrophilic bile acid, ursodeoxycho- 
lic acid, has improved liver function indices in 
patients with certain chronic liver diseases. Taurine- 
conjugated bile acids are more hydrophilic than 
glycine-conjugated bile acids, and thus, taurine admin- 
istration has also been suggested for the treatment of 
chronic hepatitis. To determine if taurine and ursode- 
oxycholic acid are beneficial and if their effects are 
additive, this double-blind, randomized trial was con- 
ducted to compare the effects of ursodeoxycholic acid, 
taurine, and a combination of the two on indices of 
liver injury in 24 patients with chronic hepatitis. 
The subjects were assigned at random to two of the 
four following treatments: ursodeoxycholic acid (600 
mg/d), taurine (1.5 g/d), ursodeoxycholic acid plus 
taurine (600 mg and 1.5 g/d) or placebo, given in two 
successive cycles of 2 months each, according to a 
balanced incomplete block design. 
As expected, ursodeoxycholic acid became the pre- 
dominant bile acid in bile when administered alone or 
in combination with taurine, and taurine conjugate 
concentrations increased during taurine adminis- 
tration. Ursodeoxycholic acid reduced serum ami- 
notransaminase and y-glutamyl transpeptidase activ- 
ities significantly, whereas taurine did not. The effects 
of taurine and ursodeoxycholic acid were not signifi- 
cantly different from those produced by ursodeoxy- 
cholic acid alone. It is concluded that ursodeoxycholic 
acid, but not taurine, improves biochemical indices of 
liver injury in patients with chronic hepatitis. 
COMMENTS 
Ursodeoxycholic acid (UDCA) has been reported to 
improve pruritus and biochemical profiles of patients 
with cholestatic liver diseases such as PBC. Several 
hypotheses have been proposed to explain these results, 
with reports based on what is known about bile acid (BA) 
metabolism, physiology and the enterohepatic circu- 
lation, but the exact mechanism(s) of these beneficial 
effects is not known. 
Chenodeoxycholic acid (CDCA) and lithocholic acid 
appear to be more toxic than more hydrophilic BAS. 
Hydrophilicity in viuo is achieved by hydroxylation 
and/or conjugation, including glucuronidation, sulfation 
and amidation with glycine or taurine. 
Taurine-conjugated BAS are more hydrophilic than 
glycine conjugates, but glycine conjugates predominate 
under normal circumstances. Previous studies have 
shown that feeding taurine to normal humans causes 
the reversal of the glycinehaurine conjugation ratio (1). 
UDCA is the 7p-epimer of CDCA. The 7P-hydroxyl 
